Latest studies
- Ongoing, recruitingTherapeutic exploratory (Phase II)
(21683) Phase 2b open-label clinical study to evaluate the tolerability and safety of an initiation dose of 5 mg of Vericiguat in participants with chronic heart failure with reduced ejection fraction
This study is testing a new 5mg dose of a drug called Vericiguat for people with long-term heart failure where their heart doesn’t pump blood well. We want to see how well people tolerate this starting dose and if it's safe to use. It's an early-stage study.
Chronic heart failure with reduced ejection fractionHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa
This study is testing new medicines for people with moderate to severe hidradenitis suppurativa, a skin condition. Researchers want to see if the new medicines can improve symptoms and are safe, compared to a dummy treatment.
Moderate to severe hidradenitis suppurativaHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study looks at a new drug called niraparib to see if it can help women with advanced ovarian cancer stay well longer after their first round of chemotherapy. It compares niraparib to a dummy pill to find out how effective and safe it is.
Homologous recombination deficiency advanced ovarian cancerHungary - Active not recruitingPHASE3
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
This study is looking at a new medicine called Olezarsen for people with very high triglyceride levels. It's an ongoing study for those who have already started the treatment in previous trials, checking its long-term safety and how well it's tolerated.
Severe HypertriglyceridemiaHungary - Active not recruitingPHASE3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This study is looking into a new medication called lanifibranor for adults with a liver condition called NASH (Nonalcoholic Steatohepatitis) and significant liver scarring (fibrosis F2 or F3). Researchers want to see if it's safe and helps improve the liver condition.
NASH - Nonalcoholic SteatohepatitisHungary - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations of deucrictibant administered as single dose under fasting condition.
This study is looking at how well different versions of a new medicine for hereditary angioedema (HAE) are absorbed by the body. Healthy volunteers will take a single dose of the medicine and have their blood checked. We want to find the best way to give this new treatment.
Hereditary angioedema (HAE)Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)
This study is testing a new inhaled medicine for people with a lung infection called MAC. It wants to see if the new medicine, given with other standard treatments, makes breathing symptoms better and helps clear the infection compared to standard treatments alone.
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"Hungary - Active not recruitingPHASE3
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study is looking at how a medication called Tirzepatide might help people living with obesity. Researchers want to see if it can reduce serious health problems and improve overall health in adults.
ObesityOverweightHungary - Active not recruitingPHASE3
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
This study is for men with a certain type of advanced prostate cancer (mCSPC) that has spread and has specific gene changes. It compares a new drug called talazoparib, given with standard treatment enzalutamide, against enzalutamide alone, to see if it's safe and effective.
Prostate CancerHungary - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
Breast NeoplasmsHungary - Active not recruitingPHASE3
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
This study looks at whether fezolinetant can reduce hot flashes in women with breast cancer who are having hormone therapy. These hot flashes are a common side effect, and current treatments like HRT aren't suitable. We want to see if fezolinetant helps more than a dummy pill.
Hot FlashesHungary - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVHungary - RecruitingPHASE1, PHASE2
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
This study is looking for new ways to treat specific childhood cancers that have come back or not responded to previous treatments. It investigates a new medicine called HER3-DXd (also known as patritumab deruxtecan) for safety and effectiveness in children aged 1 month to 17 years with hepatoblastoma or rhabdomyosarcoma.
Malignant NeoplasmHungary - RecruitingPHASE3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This study looks at a new gene therapy, Surabgene Lomparvovec, for 'wet' age-related macular degeneration (nAMD). It aims to see if it's safe and effective in reducing the need for frequent eye injections and protecting vision in adults.
Neovascular Age-related Macular DegenerationHungary - Active not recruitingPHASE3
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.
Esophageal Squamous Cell CarcinomaHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX
This study is testing a new medicine, fitusiran, for people with haemophilia A or B. It wants to see how safe and effective it is over a long time, especially in stopping bleeding. Doctors are looking at side effects and how it improves daily life.
Hemophilia A or Hemophilia BHungary - AuthorisedTherapeutic use (Phase IV)
Normal saline versus lactated Ringer’s solution for fluid administration in acute pancreatitis, an open-label multicenter randomized controlled trial: the WATERLAND trial
This study, called WATERLAND, is looking at which fluid drip is better for people with acute pancreatitis. It compares two common fluid types to see if one helps more by causing fewer serious problems or side effects.
Acute PancreatitisHungary - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung CancerHER2 MutationHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy
This study looks at a new treatment for people with a certain type of lung cancer that has been removed by surgery. It compares two medicines, Tiragolumab and Atezolizumab, against Atezolizumab alone, to see if the new combination can help prevent the cancer from coming back.
Non-Small Cell Lung CancerHungary - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
Colorectal NeoplasmsHungary - Active not recruitingPHASE3
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
This study looks at new drug combinations for a type of lung cancer called Limited-Stage Small Cell Lung Cancer (LS-SCLC). Researchers want to see if adding pembrolizumab and olaparib to standard treatments helps people live longer.
Small Cell Lung CancerHungary - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Hungary - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaHungary - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
This study is testing a new combination treatment for bladder cancer that hasn't spread. It combines standard chemotherapy and radiotherapy with a new drug called pembrolizumab, which helps your immune system fight cancer. We want to see if this new combination works better.
Urinary Bladder NeoplasmsHungary - RecruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaHungary - Active not recruitingPHASE2
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
This study is testing a new treatment, AB-1002, for a type of heart failure called non-ischemic heart failure. It aims to see if it's safe and helps improve symptoms in people whose heart failure is classed as NYHA Class III. Patients will be randomly assigned to receive the treatment or a placebo.
Congestive Heart FailureHungary - Active not recruitingPHASE3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
This study looks at two medicines, upadacitinib and adalimumab, for adults with moderate to severe Rheumatoid Arthritis (RA). It checks how safe and effective they are. Upadacitinib is a pill, and adalimumab is an injection. This helps us understand which treatment works best.
Rheumatoid ArthritisHungary - Active not recruitingPHASE3
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
This study looks at a drug called Olaparib for people in the UK with a specific type of breast cancer linked to a BRCA gene change. It aims to see if Olaparib, given after standard treatments, can help prevent the cancer from coming back.
Breast CancerHungary - RecruitingPHASE2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
This study explores a new treatment for aggressive bladder cancer that hasn't spread to the muscle. Researchers are testing if adding a new drug, intismeran autogene, to standard treatment (BCG) helps patients live longer without their cancer growing or returning. It's for adults with high-risk non-muscle invasive bladder cancer.
Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsCarcinoma in SituHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This study is looking at a new medicine called Danicopan for a type of age-related macular degeneration (AMD) called geographic atrophy (GA). Researchers want to see if the medicine can slow down vision loss and the growth of blind spots.
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)Hungary - Active not recruitingPHASE3
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
This study is testing a new drug, AZD9833, for advanced breast cancer. It's for people whose cancer has a specific gene change (ESR1 mutation) and are already on certain treatments. Researchers want to see if adding AZD9833 works better than current medicines.
ER-Positive HER2-Negative Breast CancerHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
Thromboembolic diseaseHungary - Active not recruitingPHASE4
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
This study is looking at a new treatment called guselkumab for people with psoriatic arthritis that affects the spine and pelvis. It aims to see how well it reduces pain and inflammation in these areas. Participants will receive either the study drug or a dummy treatment.
Arthritis, PsoriaticHungary - Ongoing, recruitingPhase III and phase IV (Integrated)
Lowering of LDL-C with rosuvastatin or single-pill combination rosuvastatin/ezetimibe in high/very high-risk patients with hyperlipidaemia – LEASH
This study looks at how well different medications (Sorvasta and Sorvitimb) lower 'bad' cholesterol (LDL-C) in people who have high cholesterol and are at high risk of heart problems. It checks if patients reach their target cholesterol levels after 12 weeks.
HyperlipidaemiaHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
C4391022 - AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS FULVESTRANT COMPARED TO INVESTIGATOR’S CHOICE OF THERAPY IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK 4/6 INHIBITOR-BASED THERAPY
This study looks at a new drug (PF-07220060) combined with a standard breast cancer treatment (Fulvestrant). It's for advanced hormone receptor-positive, HER2-negative breast cancer that has grown after previous CDK 4/6 inhibitor treatment. Researchers want to see if the new combination works better.
Hormone receptor-positiveher2-negative advanced/metastatic breast cancerHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome
This study is testing a new drug (tamibarotene) alongside a standard treatment (azacitidine) for adults recently diagnosed with a specific type of higher-risk myelodysplastic syndrome (MDS). It aims to see if the new combination helps more patients achieve complete remission.
Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic SyndromeHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, 52-week, Multinational, Multicenter, Randomized, Double-blind, 2-arm Parallel Group Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) With the Fixed Dose Dual Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate (CHF 1535), Both Administered Via pMDI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This study is testing a new combination inhaler for people with a lung condition called COPD. It compares a new three-in-one inhaler to an existing two-in-one inhaler over one year to see which works better and is safer for breathing and overall health.
Chronic obstructive pulmonary disease (COPD)Hungary - RecruitingPHASE3
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
This study is testing a new medicine, enlicitide, for high cholesterol. Researchers want to see if combining enlicitide with a common cholesterol medicine, rosuvastatin, works better at lowering 'bad' cholesterol than rosuvastatin alone. It's for adults aged 18-64.
HyperlipidemiaHungary - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
Heart FailureHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
Moderate to Severe Plaque PsoriasisHungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ADVANCE Outcomes)
This study is looking at a new medicine called Ralinepag for a lung condition called pulmonary arterial hypertension (PAH). It wants to see if Ralinepag can help patients feel better and prevent their condition from getting worse over time.
Pulmonary arterial hypertension (PAH)Hungary - RecruitingPHASE3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
This study is looking at a new treatment called petosemtamab for advanced head and neck cancer. It compares this new drug with standard treatments chosen by doctors, for patients whose cancer has come back or spread after previous therapies.
Head and Neck Squamous Cell CarcinomaHungary - Active not recruitingPHASE3
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
This study looks at a new combination treatment for advanced melanoma, a type of skin cancer. It compares giving a new drug called IO102-IO103 alongside an existing drug, pembrolizumab, with giving pembrolizumab alone. The aim is to see if the combination helps patients live longer without their cancer getting worse.
Metastatic MelanomaUnresectable MelanomaHungary - Active not recruitingPHASE3
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
This study is testing a new medicine called pelabresib alongside an existing treatment (ruxolitinib) for adults with myelofibrosis who haven't tried similar drugs before. It aims to see if this combination works better than ruxolitinib alone to help manage symptoms and spleen size.
MyelofibrosisPrimary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisHungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid
This study is testing new combinations of medicines for a liver condition called Primary Biliary Cholangitis (PBC). We want to see if these combinations are safe and work better than current treatments, especially for people who haven't responded well to their usual medication.
Primary Biliary Cholangitis (PBC)Hungary - Active not recruitingPHASE3
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study looks at a new medicine called concizumab for people with haemophilia A or B without inhibitors. It aims to see how well it prevents bleeding and if it's safe. Participants will take the medicine daily, usually by injection under the skin, for up to 8 years.
Haemophilia A Without InhibitorsHaemophilia B Without InhibitorsHungary - RecruitingPHASE1
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
This study is looking at a new medicine called ELVN-001 for people with a type of blood cancer called Chronic Myeloid Leukaemia (CML). It aims to find the right dose and see how safe and effective it is, especially for those who haven't responded well to other treatments.
Chronic Myeloid LeukemiaChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveCmlHungary - AuthorisedTherapeutic use (Phase IV)
Comparison of the preventive painkiller effect of etoricoxib and celecoxib after M3M surgery: A randomized, double-masked clinical trial
This study compares two pain medicines, etoricoxib and celecoxib, to see which is better at preventing pain after having a wisdom tooth (Molar 3 or M3) removed from the lower jaw. Researchers believe etoricoxib might work better.
postoperative period after mandibular M3 removalHungary - Active not recruitingPHASE3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
This study is for people with moderate to severe Hidradenitis Suppurativa who have already been treated with Secukinumab in previous studies. It looks at whether continuing this medicine or stopping it works best long-term, and how safe it is.
Hidradenitis SuppurativaHungary